Llusern Scientific completes angel syndicate-led fundraise
We have supported Llusern Scientific on securing significant investment funding from an angel syndicate backed by Angel Invest Wales and Crowdcube.
Founded in 2020, Llusern specialises in developing cutting-edge molecular diagnostic solutions that empower healthcare professionals to make faster, more informed decisions, ultimately leading to better outcomes for patients worldwide. Their flagship product, the Lodestar UTI testing system, provides rapid and accurate molecular diagnostics for Urinary Tract Infections, enabling healthcare providers to initiate targeted treatment quicker and reduce unnecessary antibiotic use.
Capital Law’s Corporate and Private Equity team advising Llusern on the investment included Hakeem Din, Athos Economides and Serra Caunt.
Hakeem Din, Associate at Capital Law said:
It has been a pleasure to support the Llusern team on another successful investment round and huge credit must go to the entire team on completing this round in such a tough current fundraising environment. It has been brilliant to see the growth of the business and the team since our initial involvement supporting them on investment from Development Bank of Wales and SFC Capital in 2023. We look forward to them deploying this new investment in what is an exciting and ambitious year ahead for Llusern and wish them continued success.
Martyn Lewis, Managing Director at Llusern said:
We have now worked with Capital Law on several fundraises and have found their support to be informed and timely. This was a complex raise in many ways and the team at Capital Law always found ways to simplify the process and speed things up so that we can get back to doing what we do best – improving the treatment and long-term health of UTI patients.
